Drug
Lapatinib clinical trials
Also written Tykerb, GW-572016, GW2016 and Tyverb.
- studies test it
- 212
- open now
- 1
- in phase 3
- 25
- first study started
- 2002
Keep track of what changes. Save the Lapatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Lapatinib
- 143
Combined with it in one product
Studies by the year they started
212 studies that test it; most in 2007 (28)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 17 |
| 2005 | 17 |
| 2006 | 18 |
| 2007 | 28 |
| 2008 | 23 |
| 2009 | 27 |
| 2010 | 16 |
| 2011 | 24 |
| 2012 | 13 |
| 2013 | 10 |
| 2014 | 7 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 68
- Phase 2
- 132
- Phase 3
- 25
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 70 · Other 142
GlaxoSmithKline (48) · National Cancer Institute (NCI) (25) · Novartis Pharmaceuticals (16) · UNC Lineberger Comprehensive Cancer Center (5) · Cancer Trials Ireland (4) · M.D. Anderson Cancer Center (4) · Baylor Breast Care Center (3) · SCRI Development Innovations, LLC (3)
Often tested with
Tested in the same studies.
Trastuzumab (31) · Paclitaxel (22) · Capecitabine (20) · Pazopanib (8) · Vinorelbine (8) · Everolimus (7) · Docetaxel (7) · Carboplatin (5)
Studies
Open first, then newest update. How each study uses Lapatinib is read from its arms, and is right about nine times in ten.
Testing it · 212
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Lapatinib (1500 mg QD)
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 2City of Hope Medical CenterNCT01273610Written as Lapatinib
- Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01947023Written as Lapatinib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Lapatinib
- Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast CancerTerminatedPhase 1/2Institut Paoli-CalmettesNCT01589861Written as BKM120 + lapatinib
- Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral SurgeryCompletedPhase 2UNC Lineberger Comprehensive Cancer CenterNCT01612351Written as Lapatinib
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in BladderTerminatedPhase 2University of Southern CaliforniaNCT01382706Written as lapatinib ditosylate
- LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibCompletedPhase 3Novartis PharmaceuticalsNCT00680901Written as Lapatinib
- Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedPhase 1/2The Netherlands Cancer InstituteNCT02230553Written as Lapatinib
- Dose Escalation of Lapatinib With Paclitaxel in Ovarian CancerCompletedPhase 1Frederick R. Ueland, M.D.NCT04608409Written as Lapatinib and Paclitaxel
- A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerCompletedPhase 3Cancer Trials IrelandNCT01526369Written as Lapatinib
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DCompletedPhase 3Novartis PharmaceuticalsNCT00490139Written as Lapatinib
- Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerCompletedPhase 3Novartis PharmaceuticalsNCT00667251Written as lapatinib ditosylate
- Extension Study of Lapatinib Plus Herceptin With or Without Endocrine TherapyActive, not recruitingPhase 2Baylor Breast Care CenterNCT00999804Written as Lapatinib
- A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedPhase 3Novartis PharmaceuticalsNCT01160211Written as Lapatinib
- Lapatinib and Capecitabine for Second Line Treatment of Pancreas CancerTerminatedPhase 2Georgetown UniversityNCT00881621Written as Lapatinib and Capecitabine
- Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast CancerCompletedPhase 2Nancy Lin, MDNCT00470704Written as Lapatinib
- Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedPhase 1National Cancer Institute (NCI)NCT02101905Written as Lapatinib
- Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedPhase 2National Cancer Institute (NCI)NCT01306045Written as Lapatinib
- A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)TerminatedPhase 1Merck Sharp & Dohme LLCNCT00963547Written as Lapatinib
See all 212 studies that test Lapatinib →
Given in every arm · 26 — Lapatinib is usual care beside what is tested
- Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedPhase 3National Cancer Institute (NCI)NCT00770809Written as Lapatinib Ditosylate
- Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast CancerCompletedPhase 1European Organisation for Research and Treatment of Cancer - EORTCNCT00424164Written as lapatinib ditosylate
- Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.CompletedPhase 1Novartis PharmaceuticalsNCT00367471Written as lapatinib
- Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00684983Written as Lapatinib Ditosylate
- Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast CancerCompletedEarly Phase 1Northwestern UniversityNCT00331630Written as lapatinib ditosylate
- Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveCompletedPhase 3National Cancer Institute (NCI)NCT00390455Written as Lapatinib Ditosylate
- Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00820872Written as lapatinib ditosylate
- Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedPhase 2Novartis PharmaceuticalsNCT02294786Written as Lapatinib
- PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerCompletedPhase 2SOLTI Breast Cancer Research GroupNCT01973660Written as Lapatinib
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as Lapatinib
- Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer AgentsCompletedPhase 1Novartis PharmaceuticalsNCT00790816Written as Lapatinib
- Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)CompletedPhase 1GlaxoSmithKlineNCT00148902Written as lapatinib
- Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TamoxifenCompletedPhase 2National Cancer Institute (NCI)NCT00118157Written as Lapatinib Ditosylate
- Lapatinib in Combination With VinorelbineCompletedPhase 2Novartis PharmaceuticalsNCT01013740Written as Lapatinib
- Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00482391Written as lapatinib ditosylate
- Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerCompletedPhase 3GlaxoSmithKlineNCT00320385Written as Lapatinib
- Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30CompletedPhase 1Cancer Trials IrelandNCT00753207Written as lapatinib ditosylate
- Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedPhase 2Translational Oncology Research InternationalNCT00769470Written as lapatinib ditosylate
- Lapatinib With Sirolimus or MetforminCompletedPhase 1M.D. Anderson Cancer CenterNCT01087983Written as Lapatinib
- Brain Metastases In ErbB2-Positive Breast CancerTerminatedPhase 2GlaxoSmithKlineNCT00437073Written as lapatinib
Showing 20 of 26.
As the comparator · 13 — what is tested is compared with Lapatinib
- A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerRecruitingPhase 3Tianjin Hemay Pharmaceutical Co., LtdNCT06313983Written as Lapatinib+Capecitabine
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedPhase 3Daiichi SankyoNCT03523585Written as Lapatinib
- A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesActive, not recruitingPhase 2/3RemeGen Co., Ltd.NCT03500380Written as Lapatinib
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedPhase 3Hoffmann-La RocheNCT03084939Written as Lapatinib
- A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingCompletedPhase 3Puma Biotechnology, Inc.NCT01808573Written as lapatinib
- A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabCompletedPhase 1Novartis PharmaceuticalsNCT01471847Written as Lapatinib + Capecitabine (Phase II)
- Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03080805Written as Lapatinib Plus Capecitabine
- The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownPhase 3Bio-Thera SolutionsNCT04185649Written as Lapatinib
- Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast CancerCompletedPhase 2Puma Biotechnology, Inc.NCT00777101Written as Lapatinib
- A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabStatus unknownPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT02422199Written as Lapatinib
- Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior TrastuzumabCompletedPhase 2ASLAN PharmaceuticalsNCT02338245Written as Lapatinib
- A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedPhase 3Hoffmann-La RocheNCT00829166Written as Lapatinib
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or TrastuzumabCompletedPhase 2Boehringer IngelheimNCT00826267Written as lapatinib
Codes
What other systems call Lapatinib · ClinicalTrials.gg INT006708
- MeSH (NLM) D000077341LapatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0VUA21238FLAPATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 480167Confirmed FDA, Wikidata
- Wikidata Q420323lapatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C26653LapatinibOne source FDA
- DrugBank DB01259One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077341 | Lapatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0VUA21238F | LAPATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 480167 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420323 | lapatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C26653 | Lapatinib | One source FDA |
| DrugBank | DB01259 | — | One source Wikidata |
Also registered as lapatinib ditosylate (UNII G873GX646R · RxNorm 481474).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.